Watch CRVO. Know when insiders buy.
One email the day a filing lands. Free.
CRVO
CervoMed Inc.
2.48
−0.03 −1.20%
USD · close Sep 10
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
16
FLAG · shorts 16
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $37.5MP/E —DIV YIELD —FCF YIELD —REV TTM $331K −95.7%NET INCOME −$30.3MNET CASH $22.4M52W 2.25 – 9.94SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $0 | −100.0% | — | −$6.7M | −$6.6M | — | -0.64 | −$6.9M | — | — | Aug 7 |
| Q1 2026 · Mar 31 | $0 | −100.0% | — | −$8.1M | −$8M | — | -0.86 | −$8M | — | — | May 15 |
| Q4 2025 · Dec 31derived | $9K | −99.6% | — | −$8.3M | −$8.1M | — | -0.88 | −$6.6M | — | — | Mar 13 |
| Q3 2025 · Sep 30 | $323K | −83.4% | — | −$8M | −$7.7M | — | -0.84 | −$6.5M | — | — | Nov 7 |
| Q2 2025 · Jun 30 | $1.8M | −46.6% | — | −$6.6M | −$6.3M | — | -0.70 | −$6.5M | — | — | Aug 7 |
| Q1 2025 · Mar 31 | $1.9M | −18.3% | — | −$5.3M | −$4.9M | — | -0.56 | −$3.9M | — | — | May 15 |
| Q4 2024 · Dec 31derived | $2.2M | −13.2% | — | −$7.2M | −$6.7M | — | -0.80 | −$8.1M | — | — | Mar 13 |
| Q3 2024 · Sep 30 | $1.9M | +27.1% | — | −$5.4M | −$4.8M | −321.1% | -0.55 | −$4.9M | — | — | Nov 7 |
| Q2 2024 · Jun 30 | $3.3M | — | — | −$3M | −$2.3M | — | -0.27 | −$2.2M | — | — | Aug 8 |
| Q1 2024 · Mar 31 | $2.3M | — | — | −$2.6M | −$2.5M | — | -0.41 | −$1.4M | — | — | May 12 |
| Q4 2023 · Dec 31derived | $2.5M | — | — | −$2.5M | −$2.4M | — | 1.55 | −$2.5M | — | — | Mar 17 |
| Q3 2023 · Sep 30 | $1.5M | — | — | −$2.7M | $2.2M | — | -0.70 | −$1.5M | — | — | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $4M | — | −$28.3M | −$27M | -673.1% | -2.98 | −$23.4M | — | — | — | — |
| FY2024 · to Dec 31 | $9.7M | — | −$18.2M | −$16.3M | -167.3% | -2.02 | −$16.5M | — | — | — | — |
| FY2023 · to Dec 31 | $7.1M | — | −$7.8M | −$2.2M | -30.4% | -0.82 | −$7.4M | — | — | — | — |
| FY2022 · to Dec 31 | $0 | — | −$3.5M | −$5.8M | — | 2038891.00 | −$2.6M | — | — | — | — |
| FY2021 · to Dec 31 | — | — | −$24.7M | −$24.1M | — | 1946859.00 | −$14.5M | — | — | — | — |
| FY2020 · to Dec 31 | — | — | −$16M | −$14.2M | — | 53831973.00 | −$13.6M | — | — | — | — |
Every number comes from CervoMed Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.